Navigation Links
New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
Date:5/31/2008

sterolemia of grade 2 or higher, compared with interferon-alpha (P=0.001), but there was not a significant increase in hyperlipidemia versus interferon-alpha (P=0.675). However, the development of hyperglycemia or hypercholesterolemia did not have affect on overall survival or progression-free survival in this study.

The clinical data for TORISEL presented at the meeting represent only a portion of the totality of the safety and efficacy data from the ongoing clinical development of TORISEL.

About TORISEL

TORISEL is an mTOR inhibitor. Inhibition of mTOR in treated cancer cells blocked the translation of genes that regulate the cell cycle. In in vitro studies using renal cancer cell lines, TORISEL inhibited the activity of mTOR and resulted in reduced levels of certain cell growth factors involved in the development of new blood vessels, such as vascular endothelial growth factor.

TORISEL is approved for the treatment of advanced RCC in the United States, European Union and other markets, based on results of a phase 3 clinical study that demonstrated that TORISEL improves overall survival for patients with advanced RCC compared with interferon-alpha.

Important Safety Information

Hypersensitivity reactions manifested by symptoms, including, but not limited to anaphylaxis, dyspnea, flushing and chest pain have been observed with TORISEL.

Serum glucose, serum cholesterol and triglycerides should be tested before and during treatment with TORISEL.

The use of TORISEL is likely to result in hyperglycemia and hyperlipemia. This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy and/or lipid-lowering agents, respectively.

The use of TORISEL may result in immunosuppression. Patients should be carefully observed for the occurrence of infections, including opportunistic infections.

Cases of interstitial lung disease, some resulting in death,
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
2. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
3. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
4. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
5. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
6. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
7. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
8. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
9. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
10. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
11. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Calif. , July 28, 2014  Isis Pharmaceuticals, ... webcast:What:Isis Pharmaceuticals, Second Quarter 2014 Financial Results and Highlights ... 7:30 a.m. PTWhere: www.isispharm.com How:Live on the Internet. ... are unable to participate during the live event, a ... limited time at www.isispharm.com . ABOUT ...
(Date:7/28/2014)... , July 28, 2014 CTI BioPharma Corp. ... will report its second quarter 2014 financial results on ... U.S. financial markets. Following the announcement, members of the ... discuss the results and provide a general corporate update ... the event can be obtained as follows: ...
(Date:7/25/2014)... , July 25, 2014  In today,s marketplace, ... costly and challenging - as is managing a portfolio ... Is it possible - or even preferable - ... so, where can you combine resources and activities, and ... These are just a few of the ...
Breaking Medicine Technology:Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2
... /PRNewswire-FirstCall/ -- Kosan,Biosciences Incorporated announced data will be ... its Hsp90,inhibitor, epothilone and nuclear export inhibitor programs, ... for Cancer Research,(AACR), being held in Los Angeles, ... programs are as follows. The,location for all poster ...
... April 10, 2007--In a study appearing in the ... by the,National Institutes of Healths National Institute of ... a,connection between a specific gene and the inflammatory ... of autoimmune,diseases. , Vitiligo is a chronic condition ...
Cached Medicine Technology:Kosan Announces Data Presentations at Upcoming AACR Annual Meeting 2Kosan Announces Data Presentations at Upcoming AACR Annual Meeting 3Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 2Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 3
(Date:7/28/2014)... patients with one of the UK,s most common respiratory ... obstructive pulmonary disease (COPD) is the name for a ... long-term damage to the lungs. Often linked to ... all hospital admissions in the UK, with a high ... are discharged. , A team of researchers, ...
(Date:7/28/2014)... Drorit Silverman, a professional bodybuilder and chiropractor ... investment capital through her crowd funding camping to tap ... States. , According to a statement released by Drorit ... a great window of opportunity for investors like her ... to this, Silverman looks at the 24/7 fitness concept ...
(Date:7/28/2014)... 28, 2014) -- Researchers from The University of Texas Health ... other institutions have identified a combination of pills that cures ... the drugs sofosbuvir and simeprevir, with or without ribavirin, cured ... tolerated by patients, according to the study published today in ... in the U.S. , Eric Lawitz, M.D., clinical professor ...
(Date:7/28/2014)... The North America Carotenoids & Antioxidants Market report ... America with analysis and forecast of revenue. This market is ... $812.7 million by 2018, at a CAGR of 7.1% from ... North America Carotenoids & Antioxidants Market report to get an ... glimpse of the segmentation in the market, and is supported ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 The Oneida ... and an incredible field of accompanying PGA TOUR players ... and golf analyst Notah Begay III for the seventh ... Turning Stone Resort Casino ’s Atunyote® Golf Club ... will include Woods, Jason Dufner, Jimmy Walker, Jonas Blixt, ...
Breaking Medicine News(10 mins):Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:New pill regimens published in The Lancet cure hardest-to-treat hepatitis C patients 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 2Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 3Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 4Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 5
... DALLAS and PLANO, Texas, March 1 Skin damage. If,you ... about you -- about,your time as a smoker (lip lines), ... age spots), or perhaps you,re,seeing a little more of Mom ... Yes, part of what you,re seeing is normal skin aging, ...
... The California,Academy of Physician Assistants (CAPA) announced that physician ... Speaker of the,California State Assembly. Bass, a member of ... former faculty member at the,University of Southern California School ... Assembly in 2004., As a physician assistant (PA), ...
... 29, 2008 A new study led by researchers at ... that can enhance the function of a protein that is ... protein, called AML1, plays a critical role in the development ... and immune cells. The findings are published in the March ...
... to be unveiled at the 2008 Orthopedic Research ... Society meeting in San Francisco, ... collaboration with RUSH University in Chicago, announces significant,findings that wear ... accelerated aging. The study, "The Effect,of Accelerated Aging on the ...
... Separate Medical ... Businesses, BATESVILLE, Ind., Feb. 29 Hillenbrand,Industries, Inc. (NYSE: ... a cash tender offer to purchase any and all of ... of which $250,million in aggregate principal amount was outstanding as ...
... small striped fish is helping scientists understand what makes people ... this case, its not the fishs ears that are of ... of the journal PLoS Genetics, researchers at the University of ... zebrafishs lateral linethe faint line running down each side of ...
Cached Medicine News:Health News:The DOT CO2 Fractional: The Next Step in Laser Skin Resurfacing 2Health News:The DOT CO2 Fractional: The Next Step in Laser Skin Resurfacing 3Health News:The DOT CO2 Fractional: The Next Step in Laser Skin Resurfacing 4Health News:Physician Assistant Karen Bass Elected Speaker Elect of California State Assembly 2Health News:Novel mechanism found that may boost impaired function of leukemia protein 2Health News:Pioneer(R) Surgical Technology, Inc. Continues to Prove Science Behind PEEK-on-PEEK(TM) Technology for Motion Preservation Devices 2Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 3Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 4Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 5Health News:Zebrafish provide useful screening tool for genes, drugs that protect against hearing loss 2Health News:Zebrafish provide useful screening tool for genes, drugs that protect against hearing loss 3
... from Thermo Labsystems was designed specifically to ... features such as the new fast dial ... microvolumes help to define this as a ... new interchangeable handle plate offers a custom ...
Research® Series 2100 Adjustable-volume Pipette, 0.5-10 µl, single-channel with adjustable-volume setting...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,412-7) or contact custom...
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... features: Eppendorf "pipette/tip" system ensures utmost ...
Medicine Products: